How best to efficiently allocate new highly effective anti-obesity medications has become a top priority among public and private payers and is being deliberated at the individual employer, health plan, state, and federal levels. Consideration of 2 distinct phases of obesity management (ie, active weight loss and maintenance of weight loss) would allow substantially more people access to these medications.